{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T19:30:31Z","timestamp":1747164631488,"version":"3.40.5"},"reference-count":43,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,14]],"date-time":"2016-12-14T00:00:00Z","timestamp":1481673600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","jfma-online.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.jfma.2017.02.013","type":"journal-article","created":{"date-parts":[[2017,4,4]],"date-time":"2017-04-04T05:19:29Z","timestamp":1491283169000},"page":"54-62","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Identification of treatment-experienced hepatitis C patients with poor cost-effectiveness of pegylated interferon plus ribavirin from a real-world cohort"],"prefix":"10.1016","volume":"117","author":[{"given":"Ta-Wei","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei-Chien","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-I","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Shan","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Chi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Min","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Chih","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuan-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Po-Cheng","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Hung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Yen","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nai-Jen","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chung-Feng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Lun","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zu-Yau","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinn-Cherng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Yen","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wan-Long","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jee-Fu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8145-1900","authenticated-orcid":false,"given":"Ming-Lung","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2017.02.013_bib1","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.jhep.2014.07.027","article-title":"Global epidemiology and genotype distribution of the hepatitis C virus infection","volume":"61","author":"Gower","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2017.02.013_bib2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.27259","article-title":"Global distribution and prevalence of hepatitis C virus genotypes","volume":"61","author":"Messina","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2017.02.013_bib3","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/hep.26141","article-title":"Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence","volume":"57","author":"Mohd Hanafiah","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2017.02.013_bib4","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1053\/j.gastro.2009.09.067","article-title":"Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression","volume":"138","author":"Davis","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2017.02.013_bib5","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jhep.2014.07.012","article-title":"Natural history of hepatitis C","volume":"61","author":"Westbrook","year":"2014","journal-title":"J Hepat"},{"key":"10.1016\/j.jfma.2017.02.013_bib6","doi-asserted-by":"crossref","first-page":"e690","DOI":"10.1097\/MD.0000000000000690","article-title":"Huge gap between clinical efficacy and community effectiveness in the treatment of chronic hepatitis C: a nationwide survey in Taiwan","volume":"94","author":"Yu","year":"2015","journal-title":"Medicine"},{"key":"10.1016\/j.jfma.2017.02.013_bib7","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1607-551X(10)70073-5","article-title":"Viral hepatitis infections in southern Taiwan: a multicenter community-based study","volume":"26","author":"Yang","year":"2010","journal-title":"Kaohsiung J Med Sci"},{"key":"10.1016\/j.jfma.2017.02.013_bib8","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/jmv.2001","article-title":"Changing prevalence of hepatitis C virus genotypes: molecular epidemiology and clinical implications in the hepatitis C virus hyperendemic areas and a tertiary referral center in Taiwan","volume":"65","author":"Yu","year":"2001","journal-title":"J Med Virol"},{"key":"10.1016\/j.jfma.2017.02.013_bib9","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/hep.21363","article-title":"A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy","volume":"44","author":"Yu","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2017.02.013_bib10","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1177\/135965350601100811","article-title":"A sustained virological response to interferon or interferon\/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan","volume":"11","author":"Yu","year":"2006","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jfma.2017.02.013_bib11","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000111703","article-title":"Long-term effects of interferon-based therapy for chronic hepatitis C","volume":"72","author":"Yu","year":"2007","journal-title":"Oncology"},{"key":"10.1016\/j.jfma.2017.02.013_bib12","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/j.1365-2036.2007.03297.x","article-title":"Sustained virological response to interferon reduces cirrhosis in chronic hepatitis C: a 1,386-patient study from Taiwan","volume":"25","author":"Huang","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jfma.2017.02.013_bib13","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000087271","article-title":"Treatment of chronic hepatitis C in southern Taiwan","volume":"49","author":"Chuang","year":"2006","journal-title":"Intervirology"},{"key":"10.1016\/j.jfma.2017.02.013_bib14","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1440-1746.2009.05789.x","article-title":"Treatment of chronic hepatitis C in Asia: when East meets West","volume":"24","author":"Yu","year":"2009","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2017.02.013_bib15","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jhep.2011.03.029","article-title":"Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon\/ribavirin","volume":"56","author":"Huang","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2017.02.013_bib16","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/hep.23976","article-title":"Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients","volume":"53","author":"Yu","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2017.02.013_bib17","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/hep.22319","article-title":"Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial","volume":"47","author":"Yu","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2017.02.013_bib18","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1136\/gut.2006.102558","article-title":"A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C","volume":"56","author":"Yu","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.jfma.2017.02.013_bib19","doi-asserted-by":"crossref","first-page":"e52048","DOI":"10.1371\/journal.pone.0052048","article-title":"Revisiting the stopping rule for hepatitis C genotype 1 patients treated with peginterferon plus ribavirin","volume":"7","author":"Yu","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jfma.2017.02.013_bib20","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1111\/jgh.12211","article-title":"Clinical utility of host genetic IL-28B variants in hepatitis C virus genotype 1 Asian patients retreated with pegylated interferon plus ribavirin","volume":"28","author":"Huang","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2017.02.013_bib21","doi-asserted-by":"crossref","first-page":"e58882","DOI":"10.1371\/journal.pone.0058882","article-title":"Virological predictors of response to retreatment in hepatitis C genotype 2 infected patients","volume":"8","author":"Huang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jfma.2017.02.013_bib22","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/hep.22871","article-title":"Retreating chronic hepatitis C with daily interferon alfacon-1\/ribavirin after nonresponse to pegylated interferon\/ribavirin: DIRECT results","volume":"49","author":"Bacon","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2017.02.013_bib23","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.dld.2006.08.007","article-title":"Pegylated interferon and ribavirin in re-treatment of responder-relapser HCV patients","volume":"39","author":"Basso","year":"2007","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jfma.2017.02.013_bib24","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1872-034X.2012.01056.x","article-title":"A multicenter survey of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan","volume":"43","author":"Oze","year":"2013","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jfma.2017.02.013_bib25","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s00535-011-0409-7","article-title":"Efficacy of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan","volume":"46","author":"Oze","year":"2011","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jfma.2017.02.013_bib26","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1053\/j.gastro.2009.01.039","article-title":"Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa\/ribavirin therapy","volume":"136","author":"Poynard","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2017.02.013_bib27","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1053\/j.gastro.2004.01.014","article-title":"Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment","volume":"126","author":"Shiffman","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2017.02.013_bib28","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1007\/s12072-010-9208-0","article-title":"Comparison of adverse effects related to pegylated interferon-based therapy for patients with chronic hepatitis B and chronic hepatitis C in Taiwan","volume":"4","author":"Yang","year":"2010","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jfma.2017.02.013_bib29","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.kjms.2016.10.008","article-title":"A real-world impact of cost-effectiveness of PegIFN\/RBV regiments on treatment-na\u00efve chronic hepatitis C patients in Taiwan","volume":"33","author":"Tsai","year":"2017","journal-title":"Kaohsiung J Med Sci"},{"key":"10.1016\/j.jfma.2017.02.013_bib30","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jhep.2014.09.013","article-title":"Randomized study of danoprevir\/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon\/ribavirin","volume":"62","author":"Feld","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2017.02.013_bib31","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1053\/j.gastro.2015.07.043","article-title":"Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection","volume":"149","author":"Foster","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2017.02.013_bib32","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jhep.2014.12.031","article-title":"Efficacy and safety of simeprevir with PegIFN\/ribavirin in naive or experienced patients infected with chronic HCV genotype 4","volume":"62","author":"Moreno","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2017.02.013_bib33","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/cld.442","article-title":"New treatments for HCV: Perspective from Asia","volume":"5","author":"Yu","year":"2015","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jfma.2017.02.013_bib34","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S1607-551X(09)70418-8","article-title":"Qualitative application of COBAS AMPLICOR HCV test version 2.0 assays in patients with chronic hepatitis C virus infection and comparison of clinical performance with version 1.0","volume":"23","author":"Hsieh","year":"2007","journal-title":"Kaohsiung J Med Sci"},{"key":"10.1016\/j.jfma.2017.02.013_bib35","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jcv.2011.07.007","article-title":"Multi-center evaluation of the Abbott RealTime HCV assay for monitoring patients undergoing antiviral therapy for chronic hepatitis C","volume":"52","author":"Vermehren","year":"2011","journal-title":"J Clin Virol"},{"key":"10.1016\/j.jfma.2017.02.013_bib36","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1099\/0022-1317-74-11-2385","article-title":"Characterization of the genomic sequence of type V (or 3a) hepatitis C virus isolates and PCR primers for specific detection","volume":"74","author":"Okamoto","year":"1993","journal-title":"J Gen Virol"},{"key":"10.1016\/j.jfma.2017.02.013_bib37","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/0168-8278(91)90084-O","article-title":"Classification of chronic viral hepatitis: a need for reassessment","volume":"13","author":"Scheuer","year":"1991","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2017.02.013_bib38","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jhep.2013.09.023","article-title":"High hepatitis B virus surface antigen levels and favorable interleukin 28B genotype predict spontaneous hepatitis C virus clearance in uremic patients","volume":"60","author":"Yu","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2017.02.013_bib39","doi-asserted-by":"crossref","first-page":"47","DOI":"10.7150\/ijms.3.47","article-title":"The natural history of hepatitis C virus (HCV) infection","volume":"3","author":"Chen","year":"2006","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.jfma.2017.02.013_bib40","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0168-8278(01)00151-9","article-title":"The spectrum of liver disease in the general population: lesson from the Dionysos study","volume":"35","author":"Bellentani","year":"2001","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2017.02.013_bib41","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/S0140-6736(98)07124-4","article-title":"Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)","volume":"352","author":"Poynard","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2017.02.013_bib42","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1136\/gut.2005.078147","article-title":"Higher clearance of hepatitis C virus infection in females compared with males","volume":"55","author":"Bakr","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.jfma.2017.02.013_bib43","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1590\/S0037-86822010000300001","article-title":"Gender influence on treatment of chronic hepatitis C genotype 1","volume":"43","author":"Narciso-Schiavon","year":"2010","journal-title":"Rev Soc Bras Med Trop"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664616304776?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664616304776?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T05:16:23Z","timestamp":1658898983000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664616304776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S0929664616304776"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2017.02.013","relation":{},"ISSN":["0929-6646"],"issn-type":[{"type":"print","value":"0929-6646"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of treatment-experienced hepatitis C patients with poor cost-effectiveness of pegylated interferon plus ribavirin from a real-world cohort","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2017.02.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Formosan Medical Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}